Естонија - Естонски - Ravimiamet

teva b.v. - everoliimus - tablett - 5mg 50tk; 5mg 10tk; 5mg 60tk; 5mg 90tk

Естонија - Естонски - Ravimiamet

gedeon richter plc. - levonorgestreel - tablett - 1500mcg 1tk

Естонија - Естонски - Ravimiamet

interhim, oao sp - bensobarbitaal - tablett - 100mg 50tk

Естонија - Естонски - Ravimiamet

alvogen ipco s.a.r.l. - montelukast - närimistablett - 4mg 7tk; 4mg 20tk; 4mg 30tk; 4mg 98tk; 4mg 100tk; 4mg 10tk; 4mg 90tk

Естонија - Естонски - Ravimiamet

teva b.v. - karboplatiin - infusioonilahuse kontsentraat - 10mg 1ml 15ml 1tk; 10mg 1ml 5ml 5tk; 10mg 1ml 5ml 1tk

Естонија - Естонски - Ravimiamet

ratiopharm gmbh - simvastatiin - õhukese polümeerikattega tablett - 20mg 30tk; 20mg 50tk

Естонија - Естонски - Ravimiamet

ratiopharm gmbh - simvastatiin - õhukese polümeerikattega tablett - 40mg 50tk

Естонија - Естонски - Ravimiamet

ratiopharm gmbh - simvastatiin - õhukese polümeerikattega tablett - 10mg 50tk; 10mg 30tk

Европска Унија - Естонски - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Европска Унија - Естонски - EMA (European Medicines Agency)

astellas pharma europe b.v. - ensalutamiid - eesnäärmevähk - endokriinset ravi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.